What It Is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that stimulates pituitary growth-hormone release.[1][2][3] It works upstream of growth hormone rather than replacing growth hormone directly.
FDA-approved tesamorelin is sold in product-specific EGRIFTA formulations for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.[1][2] EGRIFTA WR (11.6 mg per vial) and EGRIFTA SV (2 mg per vial) have different doses, reconstitution instructions, storage, and handling and are not substitutable. The approval does not cover general weight loss, bodybuilding, anti-aging, or a generic 10 mg research vial.
How It Works
Tesamorelin binds GHRH receptors on pituitary somatotroph cells, increasing growth-hormone release and downstream insulin-like growth factor-1 (IGF-1).[1][2] This differs from administering recombinant growth hormone directly.
The mechanism supports biological plausibility but does not guarantee an outcome. Current labels identify persistent IGF-1 elevation as a monitoring concern, and the effects of prolonged elevation are not established.
What the Research Shows
Randomized evidence found reduced visceral adipose tissue in adults with HIV-associated abdominal fat accumulation compared with placebo, contributing to the product's narrow approval.[5] This should not be read as general weight-loss evidence: the labels explicitly state that tesamorelin is not indicated for weight-loss management.
JAMA and The Lancet HIV trials examined liver-fat outcomes in adults with HIV and reported reductions in hepatic fat.[8][9] These findings remain outside the approved indication. Claims about muscle gain, athletic performance, or anti-aging go beyond the cited human evidence.
Safety & Side Effects
Current EGRIFTA labeling describes injection-site reactions, arthralgia, peripheral edema, myalgia, hypersensitivity, glucose intolerance, and elevated IGF-1 among the relevant adverse effects and precautions.[1][2]
- Fluid-retention effects such as edema, arthralgia, and carpal-tunnel-type symptoms
- Glucose intolerance or diabetes
- Persistent IGF-1 elevation
- Hypersensitivity reactions
Long-term cardiovascular safety has not been established. Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity, and pregnancy; the complete product-specific label controls.
Regulatory Status
Tesamorelin is FDA-approved only in specific EGRIFTA formulations for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.[1][2] The approval does not extend to general weight loss, anti-aging, athletic use, or other vial strengths.
Compounded or research-labeled tesamorelin is a separate, unapproved category. FDA does not premarket-review compounded drugs for safety, effectiveness, or quality, so a generic powder should not be assumed equivalent to either approved EGRIFTA formulation.[16]
Tesamorelin Compared to Related Growth-Hormone Peptides
CJC-1295 is another GHRH analog studied for prolonged growth-hormone and IGF-1 stimulation but lacks tesamorelin's approved indication.[13] Ipamorelin acts through a ghrelin-receptor pathway and remains investigational rather than an approved therapy.[14]
Recombinant growth hormone is a distinct hormone with separate approved indications and is not interchangeable with tesamorelin. These compounds should be compared by molecule, formulation, evidence, and regulatory status rather than by a shared online category.